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Abstract 
Purpose: To synthesize new triazole derivatives in order to overcome the problem of side effects of 
antimicrobial agents and microbial resistance, while broadening the spectrum of antimicrobial activity.    
Methods: The starting triazole, compound 1, was prepared through click chemistry and reacted with 
chloroacetyl chloride to yield compound II. Triazole 1 was reacted with acids and aldehydes to produce 
oxadiazole (III) and azomethine (IV) which cyclized in acetic anhydride to give a new acetylated 
oxadiazole (V). Minimum inhibitory concentration (MIC) and resorufin assays were used for antibacterial 
and anti-parasitic screening, respectively. Compounds II and IVb were subjected to molecular docking 
studies using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Molecular Operating Environment 
(MOE) program.   
Results: Novel oxazole-triazole derivative (III) showed high activity against Pseudomonas aeruginosa 
and moderate activity against Staphylococcus epidermidis, whereas compound IVc showed moderate 
activity against Staphylococcus epidermidis. Chloro-acetyl-triazole II and 2-hydroxyphenyl-triazole Schiff 
base (Ivb) showed pronounced activity against the kinetoplastid parasites, Leishmania major, 
Leishmania mexicana and Trypanosoma brucei.  
Conclusion: The new synthesized triazoles represent a new antimicrobial scaffold and identifies 
potential new lead compounds for follow-up and for further mechanistic studies. 
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INTRODUCTION 
 
Compounds containing triazole cores have 
numerous pharmacological activities and 
applications in the pharmaceutical field [1 - 4] . 
Combination of a triazole with triazines (3), 
pyridines (2), pyridazines (3), pyrazines (1), and 
pyrimidines (4) form new scaffolds  with 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2019 The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
Alkhadi et al 
Trop J Pharm Res, May 2019; 18(5): 1102 
 
pronounced activities. The incorporation of the 
N–C–S skeleton into triazole and thiadiazine 
produces compounds with significant 
antimicrobial activities [5]. The nucleophilic 
amino group is the center for the synthesis of 
heterocyclic rings [6] and for obtaining known 
Schiff base antimicrobial derivatives [7]. On the 
other hand, derivatives of oxadiazole are 
reported to display significant antimicrobial 
activities, and the merging of two or more 
different pharmacophores is considered a 
promising avenue for the design of potent 
antimicrobials against which resistance does not 
easily develop  [8].  
 
The main kinetoplastid pathogens are classified 
in the genera Trypanosoma and Leishmania. 
Leishmaniasis is the result of a Leishmania 
infection, whereas an infection of Trypanosoma 
brucei rhodesiense or Trypanosoma brucei 
gambiense results in sleeping sickness (human 
African trypanosomiasis, HAT). Moreover, the 
parasite Trypanosoma cruzi is responsible for 
Chagas disease, an often-fatal infection 
particularly prevalent in South and Central 
America. Worldwide, some 20 million people are 
infected with these kinetoplastid pathogens, 
resulting in estimated 95,000 deaths per year [9]. 
The main challenges of kinetoplastid disease 
therapies are extensive toxicity, lack of efﬁcacy 
and potential resistance of the Leishmania 
species [10], T. brucei [11]   and T. cruzi [12]. In 
the present study, the main target was the 
synthesis and evaluation of antimicrobial and 
anti-kinetoplastid parasite activities in new 
scaffolds of phenyl-triazole rings merged with 
azomethine, oxadiazole and acetylated 
oxadiazole rings which are expected to confer 
high antimicrobial activities with reduced 
toxicities. The target compounds were obtained 
through the synthetic pathways shown in 
Scheme 1. 
 
EXPERIMENTAL 
 
Chemistry 
 
The identities, purity and structures of the novel 
compounds were confirmed according to 
reported methods [13-15] using the following 
techniques (equipment in parenthesis): melting 
point (uncorrected, Thomas-Hoover Capillary 
Apparatus), IR (Magna FT-IR spectrometer), 
mass spectroscopy (Hewlett Packard 5988), 
NMR spectroscopy (400 MHz NMR Bruker 
device), TLC (Sigma Aldrich Company), and 
elemental analysis. Compounds I and IVa were 
prepared as reported earlier [16]. All chemicals 
were supplied from Sigma Aldrich Company. 
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Scheme 1: The synthetic pathway for target 
compounds 
Reagent and  reaction conditions: (a) chloroacetyl 
chloride, anhydrous Na2CO3, dry DMF; b) POCl3, 
benzoic acid, reflux; c) aromatic aldehyde, ethanol, 
reflux; d) acetic anhydride, reflux 
 
Chloroacetic acid N-[2-(4-phenyl-[1, 2, 3] 
triazol-1-yl) acetyl] hydrazide (II)   
 
The hydrazide compound I (0.01 mole) was 
dissolved in dry DMF (20 mL) containing 
anhydrous sodium carbonate (1 g). 
Chloroacetyl chloride (0.015 moles) was added 
dropwise to stirred solution of the hydrazide. 
The reaction solution was continually stirred for 
4 h, and was thereafter neutralized with sodium 
carbonate solution (10 %) until alkaline to 
litmus paper. The product was filtered, washed 
with ice-cooled water, dried and crystallized 
from ethanol. 
 
2-Phenyl-5-(4-phenyl-[1, 2, 3]-triazol-1-
ylmethyl) [1, 3, 4] oxadiazole (111) 
 
The mixture of hydrazide compound I (0.01 
mole) and benzoic acid (0.01 mole) was added 
to phosphorus oxychloride (30 mL). The 
reaction mixture was refluxed for 8 h after 
which it was cooled in an ice bath and added to 
crushed ice (100 g). The reaction solution was 
then neutralized with sodium carbonate solution 
(10 %) until it became basic to litmus paper. 
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The precipitated product was filtered and 
washed with cold water. Then, compound III 
was crystallized from ethanol. 
 
Preparation of compounds IVa - IVd 
 
Appropriate amounts of aldehyde (0.01 mole) 
and hydrazide compound I (0.01 mole) in 
ethanol (50 mL) with two drops of glacial acetic 
acid, were refluxed for 10 h. The reaction 
solution was cooled in ice bath, filtered, and 
crystallized from ethanol. 
 
Synthesis of compounds Va - Vc 
 
Azomethine compound IV (0.01 mole) and acetic 
anhydride (30 mL) were refluxed for 10 h. The 
reaction solution was cooled in ice bath and 
continuously stirred with distilled water (100 mL) 
for 6 h. Thereafter, the new oxadiazoles were 
filtered and crystallized from ethanol. 
 
Assessment of antibacterial activity 
 
The microorganisms used were ATCC or LMG 
standard isolates kindly provided by Beni-Suef 
University, Faculty of Pharmacy Microbiology 
and Immunology Department. The minimum 
inhibitory concentrations (MICs) of the 
synthesized compounds were determined using 
the agar dilution method according to the Clinical 
Laboratory Standards Institute (CLSI) [17]. For 
each sample, different concentrations were 
diluted with Muller Hinton agar to give final 
concentrations ranging from 200 to 6.25 µg/mL. 
Dimethyl sulphoxide (DMSO) was used as a 
negative control plate. All bacterial isolates were 
sub-cultured on Brain Heart Infusion Agar (BHIA) 
and incubated at 37 °C for 24 h [17]. Each 
experiment was performed in duplicate. 
 
Determination of anti-kinetoplastid activity  
 
All parasite strains were kept and cultured at the 
University of Glasgow, and were standard strains 
used in many published papers [28]. 
 
Culturing of Trypanosoma brucei blood-
stream forms (BSF) in-vitro 
 
Two strains of the bloodstream forms of 
Trypanosoma brucei were utilized. The first strain 
was the wild type of Trypanosoma brucei (s427-
WT) and the other was clone B48, which was 
acquired from a TbAT1-KO strain created by the 
genetic deletion of the TbAT1 gene from s427-
WT, followed by in vitro exposure to incremental 
concentrations of pentamidine, creating a high 
level of resistance to pentamidine, diminazene 
and melaminophenyl arsenicals [19]. The 
culturing of Trypanosoma brucei bloodstream 
forms (BSF) in vitro was done according to the  
method reported earlier [20]. 
 
Culturing of Leishmania major and 
Leishmania mexicana promastigotes 
 
Leishmania major strain Friedlin (LmjF) and a 
strain of Leishmania mexicana (MNYC/BZ/62/ 
M379) were propagated in essential medium 
(HOMEM) at a pH of 7.4 and were supplemented 
with a 10 % heat-inactivation FCS at 25 ºC, as 
described earlier [21]. The resultant cultures 
were then passed through fresh medium three 
times per week. 
 
Resorufin assay  
 
Resorufin sodium salt (Alamar blue) is usually 
used as an indicator of cell metabolic functions. It 
is a non-fluorescent blue dye that is metabolized 
by live cells to a red fluorescent compound 
resorufin. The assay  was done according to the 
method reported in [22]. 
 
Alamar blue assay  
 
This assay was essentially performed as 
described previously [23].  Drug solutions (20 
mM) for testing in the resazurin assay were 
prepared in DMSO, ensuring a final 
concentration of exactly 0.5 % DMSO in the cell 
suspension (this level of DMSO does not 
influence cell growth). Plates (96-well) were set 
up with test concentrations starting from 100 µM 
and 23 double dilutions over two rows of the 
plate, with the final well used as a drug-free 
control. Each well of the plate received 100 µL of 
medium; the first well in the dilution series also 
received 100 µL of the 200 µM test compound; 
100 µL went to the next well and so on, until 23 
dilutions were made. To each well was then 
added 100 µL of cell suspension containing 2 × 
105 cells/mL, and the plates were incubated for 
48 h at 37 ºC in an incubator containing 5 % CO2,  
after which 20 µL of the resazurin solution was 
added to each well, followed by a further 24 h 
incubation. Fluorescence was then read using a 
FLUOstar Optima fluorimeter (BMG Labtech; 
λexcitation = 530 nm and λemission = 590 nm). The 50 
% effective concentrations (EC50) were 
calculated from a plot of the data using the 
equation for a sigmoidal curve with a variable 
slope, with Prism 5.0 software (GraphPad 
Software Inc., California, USA). 
 
Resazurin assay  
 
The resazurin assay for L. major promastigotes 
and L. mexicana was performed exactly as 
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described earlier [24]. It was very similar to the 
procedure for Trypanosoma brucei, except for 
the use of HOMEM medium (Section 3.3.2) and 
1 × 105 cells per well. The incubation time was 
72 h prior to the addition of the resazurin 
solution, with additional incubation for 24 h after 
the addition. 
 
Molecular modelling studies 
 
In this study, Molecular Operating Environment 
(MOE) version 2010.08 (Chemical Computing 
Group Inc., Montreal, Quebec, Canada) was 
used in the docking experiments. The crystal 
structure of nicotinamide adenine dinucleotide 
(NAD) bound to glyceralde-3-phosphate 
dehydrogenase (GADPH, PDB: ID 1GYP) was 
obtained from the RCSB Protein Data Bank. 
Docking of the co-crystallized ligands was used 
to study the scoring energies, root mean values, 
and interactions of amino acids [18]. 
 
RESULTS 
 
Spectra data 
 
Chloroacetic acid N-[2-(4-phenyl-[1, 2, 3] 
triazol-1-yl) acetyl] hydrazide (II). White 
powder (90 %); mp 180 - 184 °C; IR (film) 3109 
(NH), 3074(CH, aromatic), 2960 (CH, aliphatic), 
1666 (broad, 2C=O) cm-1; 1HNMR (DMSO-d6) δ 
4.46(s, 2H, CH2Cl) ,5.60 (s, 2H, CH2), 7.34-
7.38 (m, 1H, phenyl H-4), 7.45- 7.48 (m, 2H, 
phenyl H-3,5), 7.88-7.89 (m, 2H, phenyl H-2,6), 
8.71 (s, 1H, triazole H) , NH peaks  not 
observable; 13C NMR (DMSO-d6) δ 44.47, 
50.75, 122.69, 123.43, 125.62, 129.44, 130.76, 
146.69, 152.86, 162.05; EIMS (m/z) 293 (M+., 
12.79%), 45 (100%); Anal. Calcd for 
C12H12ClN5O2: C, 49.07; H, 4.12; N, 23.84; 
found: C, 49.10; H, 4.10; N, 23.80. 
 
2-Phenyl-5-(4-phenyl-[1, 2, 3]-triazol-1-
ylmethyl) [1, 3, 4]oxadiazole (111). Dirty white 
powder (60%); mp 258-260 °C; IR (film) 
3039(CH, aromatic), 2900 (CH, aliphatic), 1600 
(C=N) cm-1; 1H NMR (DMSO-d6) δ 5.30, 5.32 
(s, 2H, CH2), 7.36-7.47 (m, 6H, two phenyl H-
3,4,5), 7.86-7.88 (m, 4H, two phenyl H-2,6), 
8.56(s, 1H, triazole H); Anal. Calcd for 
C17H13N5O: C, 67.32; H, 4.32; N, 23.09; found: 
C, 67.50; H, 4.20; N, 23.00. 
 
(4-Phenyl-[1,2,3]-triazol-1-yl) acetic acid (2-
hydroxybenzylidene) hydrazide (IVb). White 
powder (70%); mp 233-235 °C; IR (film) 3487 
(OH), 3444 (NH), 1697 (C=O), 1616 (C=N) cm-
1;1H NMR (DMSO-d6) δ 5.33,5.74 (s, 2H, CH2), 
6.86-6.93 (m, 2H, hydroxylphenyl-H-3, H-5), 
7.25-7.37(m, 2H, hydroxyphenyl H-4, phenyl H-
4), 7.45-7.49 (m, 2H, phenyl H-3,5), 7.80-
7.81(m, 1H, hydoxyphenyl H-6), 7.87-7.90(m, 
2H, phenyl H-2,6), 8.30 (s,1H, triazole), 8.56 (s, 
H, N=CH), 10.2 (s, 1H, NH), 11.82(s, 1H, OH, 
D2O exchangeable); 13C NMR (DMSO-d6) δ 
51.47, 116.63, 119.91, 120.46, 123.46, 125.59, 
126.41, 128.40, 131.11, 132.19, 142.26, 
146.78. 148.33, 156.94, 167.47; Anal. Calcd for 
C17H15N5O2: C, 63.54; H, 4.71; N, 21.79; found: 
C, 63.50; H, 4.60; N, 21.90. 
 
(4-Phenyl-[1, 2, 3]-triazol-1-yl) acetic acid (4-
nitrobenzylidene) hydrazide (IVc). Yellowish 
white powder (90%); mp 226-228 °C; IR (film) 
3452 (NH), 1697 (C=O), 1627 (C=N) cm-1; 1H 
NMR (DMSO-d6) δ 5.30-5.82 (m, 2H, CH2), 7.34-
7.35 (m, 2H, phenyl H-2,6), 7.44-7.48(m, 3H, 
phenyl H-3,4,5), 7.85-7.89 (m, 3H, triazole-H, 4-
nitrophenyl H-2,6), 8.02-8.37 (m, 2H, nitrophenyl 
H-3,5), 8.51-8.61 (m, 2H, NH, N=CH); 13C NMR 
(DMSO-d6) δ 51.36, 123.70, 124.51, 125.59, 
128.50, 129.40, 131.07, 131.18, 140.64, 142.70, 
153.05, 157.54, 167.84. Anal. Calcd for 
C17H14N6O3: C, 58.28; H, 4.03; N, 23.99; found: 
C, 58.10; H, 4.10; N, 24.00. 
 
(4-Phenyl-[1, 2, 3] triazol-1-yl) acetic acid (3, 
4-dimethoxybenzylidene) hydrazide (IVd). 
White powder (75%); mp 203-205 °C; IR (film) 
3262 (NH), 3001(CH, aromatic), 2927(CH, 
aliphatic), 1697 (C=O)cm-1; 1H NMR (DMSO-d6) 
δ 3.44 (s, 3H, 4-OCH3), 3.47(s, 3H, 3OCH3), 
5.57(s, 2H, CH2), 7.32-7.36 (m, 2H, 
dimethoxyphenyl-H-2,5), 7.44-7.48 (m, 4H, 
dimethoxyphenyl H-6, phenyl H-3, 4, 5), 7.86-
7.88 (m, 3H, phenyl H-2,6, triazole H), 8.54 (s, H, 
N=CH), 10.63 (s, 1H, NH); 13C NMR (DMSO-d6) 
δ 51.33, 51.38, 55.96, 56.54, 123.45, 123.70, 
125.57, 128.28, 128.35, 129.41, 131.15, 131.27, 
146.58, 146.68, 153.03, 157.56, 167.84; Anal. 
Calcd for C19H19N5O3: C, 62.46; H, 5.24; N, 
19.17; found: C, 62.40; H, 5.30; N, 19.10. 
 
1-[2-Phenyl-5-(4-phenyl [1, 2, 3]-triazol-1-
ylmethyl) [1, 3, 4] oxadiazol-3-yl] ethanone 
(Va). Dirty white powder (60%); decomposition 
>300 °C; IR (film), 3039(CH, aromatic), 2900 
(CH, aliphatic), 1600 (C=N) cm-1 ; 1H NMR 
(DMSO-d6) δ 2.14 (s, 3H, CH3), 5.57-5.60 (m, 
2H, CH2), 6.96 (s, 1H, oxadiazole CH), 7.30-7.34 
(m, 2H, oxazolophenyl H-3,5), 7.36-7.44 (m, 6H, 
oxazolophenyl H-2,6,4, phenyl H-3, 4,5), 7.6-
7.82(m, 2H, phenyl H-6,2), 8.41 (s, 1H, triazole 
H); 13C NMR (DMSO-d6) δ 11.48, 51.26, 91.87, 
122.87, 123.19, 125.45, 126.91, 127.12, 128.36, 
129.15, 131.08, 136.30, 146.64, 157.96, 162.43; 
Anal. Calcd for C19H17N5O2: C, 65.69; H, 4.93; N, 
20.16; found: C, 65.60; H, 4.90; N, 20.20. 
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1-[2-(4-Nitrophenyl-5-(4-phenyl-[1, 2, 3]  
triazol-1-ylmethyl)–[1, 3, 4]–oxadiazol-3-yl] 
ethanone (Vb). Dirty white powder (60%); 
mp328-330 °C; IR (film) 3070(CH, aromatic), 
2900 (CH, aliphatic), 1660 (C=O), 1604 (C=N) 
cm -1; 1H NMR (DMSO-d6) δ1.92 (s, 3H, CH3), 
5.62-5.65 (m, 2H, CH2), 7.18 (s, 1H, oxadiazole 
H) , 7.32-7.34 (m, H, phenyl H-4), 7.42-7.45 (m, 
2H, phenyl H-3,5), 7.77-7.88(m, 4H, phenyl H-
6,2, nitrophenyl H-2,6), 8.28(d, 2H, J = 8.8Hz, 
nitrophenyl H-3,5), 8.46 (s, 1H, triazole H); 13C 
NMR (DMSO-d6) δ 20.85, 50.76, 90.50, 123.23, 
124.42, 125.59, 128.39, 129.20, 131.00, 142.01, 
146.72, 148.85, 158.08, 164.90, 172.97. Anal. 
Calcd for C19H16N6O4: C, 58.16; H, 4.11; N, 
21.42; found: C, 58.20; H, 4.10; N, 21.40. 
 
1-[2-(3,4-Dimethoxyphenyl)-5-(4-phenyl-
[1,2,3]triazol-1-ylmethyl)–[1,3,4]- oxadiazol-3-
yl-] -ethanone (Vc). Dirty white powder (60%); 
mp 278-280; IR (film) 3074(CH, aromatic), 2950 
(CH, aliphatic), 1693 (C=0) cm-1; 1H NMR 
(DMSO-d6) δ 2.04 (s, 3H, CH3), 3.62, 3.63 (s, 
6H, 2 OCH3), 5.10 (s, 2H, CH2), 7.32-7.46 (m, 
7H, oxadiazole H, dimethoxyphenyl H-2, 5,6, 
phenyl H-3,4,5 ), 7.81-7.83 (m, 2H, phenyl H-
6,2), 8.45 (s, 1H, triazole H); Anal. Calcd for 
C21H21N5O4: C, 61.91; H, 5.20; N, 17.19; found: 
C, 61.80; H, 5.30; N, 17.20. 
 
Antibacterial activity   
 
Results of the antibacterial and antifungal 
screening were verified as MICs; the MIC is the 
lowermost concentration of antibacterial 
/antifungal agents that causes almost complete 
inhibition of growth. The results are shown in 
Table 1. The inhibitory effects of the new 
compounds were screened against the following 
microorganisms (Klebsiella sp. (Kleb.), Listeria 
innocua (Lis.), Proteus vulgaris (Prot.), 
Micrococcus sp.(Micr.), Staphylococcus 
epidermidis (Staph.), Candida albicans (Ca. 1), 
Candida kruzi (Ca. 2), Klebsiella pneumonia (Kl. 
Pn.), Escherichia coli (E. coli), Acinetobacter 
sp.(Acin.), Enterococcus faecium (Ent.), 
Vancomycin Resistant Staphylococcus aureus 
(VRSA), Bacillus sp. (Ba.), Streptococcus 
pyogenes (Strep.), Escherichia coli (E. coli 2), 
Enterococcus faecalis (Enter.), Sarcina lutea 
(Sar.), and Pseudomonas aeruginosa (Ps.). 
There were no activity except for compounds III, 
IVd and Vc which produced potent activity 
against Pseudomonas aeruginosa. Compounds 
III and IVc showed moderate activity against 
Staphylococcus epidermidis. 
 
Trypanosoma brucei bloodstream forms 
(BSF) in-vitro 
 
In this research, two strains of the bloodstream 
forms of Trypanosoma brucei were utilized. The 
first was a standard drug-sensitive laboratory 
strain of Trypanosoma brucei (s427-WT). The 
other was TbAT1-B48, which was derived from 
s427-WT through a genetic knockout of the 
TbAT1/P2 drug transporter, followed by exposure 
to a gradual increase in the concentration of 
pentamidine [19]. It is usually highly resistant to 
pentamidine and diminazene as well as 
melaminophenyl arsenicals, lacking both the 
TbAT1/P2 transporter and the high-affinity 
pentamidine transporter [18]. The results are 
shown in Table 2. 
 
Table 1: Antibacterial effects of the new compounds 
(MIC, µg/ml) 
 
Compound Staphylococcus  epidermidis 
Pseudomonas  
aeruginosa 
II ˃100 ˃100 
III 50 12.5 
IVb ˃100 ˃100 
IVc 50 100 
IVd ˃100 25 
Va ˃100 ˃100 
Vb ˃100 ˃100 
Vc ˃100 50 
Ampicillin 0.7 >100 
 
Anti-kinetoplastid parasite activity 
 
Promastigotes of Leishmania major and 
Leishmania mexicana 
 
The antileishmanial activity closely mirrored the 
activity against the related kinetoplastid 
parasite T. brucei (Table 2), with compounds II 
and IVb displaying EC50 values of 10.1 ± 2.1 
µM and 18.0 ± 0.8 µM, respectively, against L. 
major promastigotes.  
 
Compounds II and IVb had moderate inhibitory 
effects against kinetoplastid parasite, while the 
other compounds showed no activity. 
 
Molecular docking results 
 
In an attempt to explore the mechanisms of 
action of the newly synthesized target 
compounds as anti-kinetoplastid parasite 
agents, the compounds were subjected to 
molecular docking studies using 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) which catalyzes the sixth reaction in 
the glycolytic sequence [20])  In kinetoplastids 
such as Trypanosoma and Leishmania, the 
glycolytic   pathway   is    localized   mainly    in  
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Table 2: Anti-kinetoplastid parasite effects of the new compounds (EC50, µM) 
 
Compound Trypanosoma brucei 
brucei (WT) 
Trypanosoma brucei 
brucei (B48) 
L. major, 
promastigotes 
L. mexicana, 
promastigotes 
II 9.10 ± 0.2 10.7 ± 0.7 10.10 ± 2.10 5.10± 0.3 
III >100 >100 >100 >100 
IV a >100 >100 >100 >100 
IV b 8.6 ± 0.6 8.8± 0.60 18 ± 0.8 28.10 ± 3.80 
IV c >100 >100 >100 >100 
IV d >100 >100 >100 >100 
Va >100 >100 >100 >100 
Vb >100 >100 >100 >100 
Vc >100 >100 >100 >100 
Pentamidine 0.005 ± 0.001 0.37 ± 0.01 4.340 ± 0.172 1.247 ± 0.113 
Values are mean ± SEM) 
 
 
 
Figure 1:  Binding of NAD inside glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). (A) 3D 
interactions of NAD with (GAPDH) using MOE site 
finder program. The red dotted line represents H-
bonding interactions between –OH and –PO4 groups 
and Asp38 and Iie13 amino acids. (B) 2D 
interactions of NAD with GAPDH 
 
 
 
Figure 2: Binding of compound II inside GAPDH. (A) 
3D interactions of compound II within GAPDH using 
MOE site finder program. The dotted lines represent 
three H-bonding interactions between N of triazole 
moiety and IIe13. (B) 2D interactions of compound II 
with GAPDH. 
 
 
 
Figure 3: Binding of compound IVb inside GAPDH. 
(A) 3D interactions of compound IVb within GAPDH 
using MOE site finder program. The dotted lines 
represent two H-bonding interactions between NH 
group and Asp38, and OH with Arg15. (B) 2D 
interactions of compound IVb with GAPDH 
 
Table 3: Molecular modeling data for compounds II, 
IVb and NAD during docking in GAPDH 
 
Compoun
d  
 
Affinit
y 
(kcal/
mol) 
No. of 
Hydro
gen 
bonds 
Distance 
(Å) from 
main 
residue 
Functi
onal 
group 
II -16.34 1 IIe1
3 
2.
41 
N of 
triazole 
IV b -16.22 2 Asp
38 
Arg
15 
2.
35 
2.
67 
NH 
OH 
Ligand 
(NAD) 
-15.24 2 Asp
38 
IIe1
3 
2.
66 
2.
52 
OH 
PO4 
 
glycosomes [23, 24]. The bindings of 
compounds II and IVb to GAPDH are shown in 
Figures 1 - 3. 
 
DISCUSSION 
 
The structure of chloroacetyl-triazole II was 
confirmed by NMR in which the new NMR 
peaks that appeared at δ 4.46 (HNMR) and 
44.47 (CNMR) were equivalent to CH2Cl, and 
the presence of chloride in the mass spectra 
confirmed the structure of chloro-acetyl-triazole 
II. The disappearance of the carbonyl group 
peaks in the IR spectrum and NH peaks in the 
1H-NMR spectra indicated the structure of 
oxadiazole-triazole III. The molecular structure 
of each azomethine derivative was confirmed 
by the appearance of new and characteristic 
de-shielded azomethine peaks (CH=N) and the 
disappearance of NH2 peaks. The azomethine 
CH peak appeared at δ 8.51-8.61 ppm, while 
the methoxy groups of azomethine derivatives 
appeared in the aliphatic region in the 1H-NMR 
or 13C-NMR spectra. The methoxy group peaks 
appeared at δ 3.37-3.85 (1H-NMR) and 50-56 
(13C-NMR) ppm. The new phenolic (OH) peak 
of compound IVb appeared at δ 11.82 ppm (1H-
NMR). New NMR peaks (of methyl group) 
indicating the acetyl moiety appeared at δ 1.92-
Alkhadi et al 
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2.14 (1H-NMR) and 11-20 (13C-NMR) ppm, and 
confirm the structure of oxadiazole derivatives 
Va-Vc. 
 
Only compound oxadiazole III displayed activity 
against Pseudomonas aeruginosa, with an MIC 
of 12.5 µg/mL, which may be attributed to the 
presence oxadiazole ring. 
 
The chloroacetyl compound II and azomethine 
containing hydroxyl group IVb, displayed 
moderate activity against T. brucei, with EC50 
values close to 10 µM, and importantly, no loss 
of activity against the multi-drug resistant strain 
B48. The moderate activities of compounds II 
and IVb may be due to their polarity. 
 
It was observed that the EC50 values against L. 
mexicana were very similar to those found 
against L. major, confirming that the scaffolds 
have broad activity against kinetoplastid 
parasites, and that the anti-kinetoplastid activity 
could be further improved by exploring more of 
the structure-activity relationships and 
identifying the targets to enable structure-aided 
design. 
 
Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) is an attractive drug target in 
trypanosomes since their bloodstream forms 
lack the citric acid cycle and the classical 
electron transport chain in their minimalized 
mitochondrion, making them depend solely on 
glycolysis for their energy requirements. 
Glyceraldehyde 3-phosphate dehydrogenase 
from the pathogenic trypanosomatids T.  brucei 
is quite similar to GAPDH from Leishmania 
Mexicana. However, the GAPDH in these 
pathogens is structurally different from the 
human GAPDH. This difference is exploited in 
the structure-based design of compounds that 
selectively inhibit the trypanosomatid enzymes 
but not the human homologue. Moreover, 
GAPDH was used in the present study as a 
target hunt. The novel synthesized triazole- 
oxazole scaffold has promising antimicrobial 
activity as a result of its multi-targets and 
mutual combination of two active structures. 
 
CONCLUSION 
 
The oxadiazole nucleus of compound Vc or non-
acetylated III has important antibacterial activity, 
especially against Pseudomonas aeruginosa. 
However, the 2-hydroxy group in compound IVb 
and the chloroacetyl group in compound II 
strongly improve the anti-parasitic activities of 
these compounds; they may affect the 
conformation of the structure with respect to 
formation of H-bonds with GAPDH receptors, if 
GAPDH is confirmed to be the cellular target. 
Thus, the antimicrobial activity of the novel 
triazoles may be beneficial for the discovery of 
new antimicrobial drugs. 
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